Long-term Risk of Bleeding Events in Patients Taking Antithrombotic Agents for Cerebrovascular or Cardiovascular Disease - PubMed
3 hours ago
- #Bleeding Risk
- #Antithrombotic Therapy
- #Cardiovascular Disease
- Antithrombotic agents are crucial for preventing cerebrovascular and cardiovascular diseases but pose bleeding risks, especially in elderly patients and those on combination therapy.
- The BAT2 Study, a prospective multicenter registry in Japan, assessed bleeding risks in patients on antithrombotic therapy over 2 years.
- Major findings include higher risks of major bleeding with DOAC, warfarin, and DOAC plus antiplatelet therapy compared to single antiplatelet therapy (SAPT).
- Intracranial hemorrhage (ICH) risks were significantly higher with DAPT, warfarin, and DOAC plus AP compared to SAPT.
- Ischemic event risks were elevated in DAPT, DOAC plus AP, and warfarin plus AP groups compared to SAPT.
- The study highlights the need for careful consideration of antithrombotic therapy combinations due to varying risks of bleeding and ischemic events.